Literature DB >> 20679399

Developmental stage-specific interplay of GATA1 and IGF signaling in fetal megakaryopoiesis and leukemogenesis.

Jan-Henning Klusmann1, Frank J Godinho, Kirsten Heitmann, Aliaksandra Maroz, Mia Lee Koch, Dirk Reinhardt, Stuart H Orkin, Zhe Li.   

Abstract

Oncogene-mediated transformation of hematopoietic cells has been studied extensively, but little is known about the molecular basis for restriction of oncogenes to certain target cells and differential cellular context-specific requirements for oncogenic transformation between infant and adult leukemias. Understanding cell type-specific interplay of signaling pathways and oncogenes is essential for developing targeted cancer therapies. Here, we address the vexing issue of how developmental restriction is achieved in Down syndrome acute megakaryoblastic leukemia (DS-AMKL), characterized by the triad of fetal origin, mutated GATA1 (GATA1s), and trisomy 21. We demonstrate overactivity of insulin-like growth factor (IGF) signaling in authentic human DS-AMKL and in a DS-AMKL mouse model generated through retroviral insertional mutagenesis. Fetal but not adult megakaryocytic progenitors are dependent on this pathway. GATA1 restricts IGF-mediated activation of the E2F transcription network to coordinate proliferation and differentiation. Failure of a direct GATA1-E2F interaction in mutated GATA1s converges with overactive IGF signaling to promote cellular transformation of DS fetal progenitors, revealing a complex, fetal stage-specific regulatory network. Our study underscores context-dependent requirements during oncogenesis, and explains resistance to transformation of ostensibly similar adult progenitors.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20679399      PMCID: PMC2912563          DOI: 10.1101/gad.1903410

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  51 in total

1.  E2F repression by C/EBPalpha is required for adipogenesis and granulopoiesis in vivo.

Authors:  B T Porse; X Xu; B Lindberg; U M Wewer; L Friis-Hansen; C Nerlov
Journal:  Cell       Date:  2001-10-19       Impact factor: 41.582

2.  Probing tumor phenotypes using stable and regulated synthetic microRNA precursors.

Authors:  Ross A Dickins; Michael T Hemann; Jack T Zilfou; David R Simpson; Ingrid Ibarra; Gregory J Hannon; Scott W Lowe
Journal:  Nat Genet       Date:  2005-10-02       Impact factor: 38.330

3.  E2F integrates cell cycle progression with DNA repair, replication, and G(2)/M checkpoints.

Authors:  Bing Ren; Hieu Cam; Yasuhiko Takahashi; Thomas Volkert; Jolyon Terragni; Richard A Young; Brian David Dynlacht
Journal:  Genes Dev       Date:  2002-01-15       Impact factor: 11.361

Review 4.  Pattern of malignant disorders in individuals with Down's syndrome.

Authors:  H Hasle
Journal:  Lancet Oncol       Date:  2001-07       Impact factor: 41.316

5.  GATA-1-mediated proliferation arrest during erythroid maturation.

Authors:  Marcin Rylski; John J Welch; Ying-Yu Chen; Danielle L Letting; J Alan Diehl; Lewis A Chodosh; Gerd A Blobel; Mitchell J Weiss
Journal:  Mol Cell Biol       Date:  2003-07       Impact factor: 4.272

6.  Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome.

Authors:  Joshua Wechsler; Marianne Greene; Michael A McDevitt; John Anastasi; Judith E Karp; Michelle M Le Beau; John D Crispino
Journal:  Nat Genet       Date:  2002-08-12       Impact factor: 38.330

7.  RUNX1 and GATA-1 coexpression and cooperation in megakaryocytic differentiation.

Authors:  Kamaleldin E Elagib; Frederick K Racke; Michael Mogass; Rina Khetawat; Lorrie L Delehanty; Adam N Goldfarb
Journal:  Blood       Date:  2003-02-06       Impact factor: 22.113

8.  A stem cell molecular signature.

Authors:  Natalia B Ivanova; John T Dimos; Christoph Schaniel; Jason A Hackney; Kateri A Moore; Ihor R Lemischka
Journal:  Science       Date:  2002-09-12       Impact factor: 47.728

9.  Nuclear factor E2F mediates basic transcription and trans-activation by E1a of the human MYC promoter.

Authors:  K Thalmeier; H Synovzik; R Mertz; E L Winnacker; M Lipp
Journal:  Genes Dev       Date:  1989-04       Impact factor: 11.361

10.  Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection.

Authors:  C Li; W H Wong
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-02       Impact factor: 11.205

View more
  62 in total

Review 1.  p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies.

Authors:  Yogen Saunthararajah; Pierre Triozzi; Brian Rini; Arun Singh; Tomas Radivoyevitch; Mikkael Sekeres; Anjali Advani; Ramon Tiu; Frederic Reu; Matt Kalaycio; Ed Copelan; Eric Hsi; Alan Lichtin; Brian Bolwell
Journal:  Semin Oncol       Date:  2012-02       Impact factor: 4.929

Review 2.  Normal and malignant megakaryopoiesis.

Authors:  Qiang Wen; Benjamin Goldenson; John D Crispino
Journal:  Expert Rev Mol Med       Date:  2011-10-21       Impact factor: 5.600

3.  Global transcriptome and chromatin occupancy analysis reveal the short isoform of GATA1 is deficient for erythroid specification and gene expression.

Authors:  Timothy M Chlon; Maureen McNulty; Benjamin Goldenson; Alexander Rosinski; John D Crispino
Journal:  Haematologica       Date:  2015-02-14       Impact factor: 9.941

4.  Neonatal expression of RNA-binding protein IGF2BP3 regulates the human fetal-adult megakaryocyte transition.

Authors:  Kamaleldin E Elagib; Chih-Huan Lu; Goar Mosoyan; Shadi Khalil; Ewelina Zasadzińska; Daniel R Foltz; Peter Balogh; Alejandro A Gru; Deborah A Fuchs; Lisa M Rimsza; Els Verhoeyen; Miriam Sansó; Robert P Fisher; Camelia Iancu-Rubin; Adam N Goldfarb
Journal:  J Clin Invest       Date:  2017-05-08       Impact factor: 14.808

5.  Tumorigenesis in Down's syndrome: big lessons from a small chromosome.

Authors:  Dean Nižetić; Jürgen Groet
Journal:  Nat Rev Cancer       Date:  2012-09-21       Impact factor: 60.716

6.  Perturbation of fetal liver hematopoietic stem and progenitor cell development by trisomy 21.

Authors:  Anindita Roy; Gillian Cowan; Adam J Mead; Sarah Filippi; Georg Bohn; Aristeidis Chaidos; Oliver Tunstall; Jerry K Y Chan; Mahesh Choolani; Phillip Bennett; Sailesh Kumar; Deborah Atkinson; Josephine Wyatt-Ashmead; Ming Hu; Michael P H Stumpf; Katerina Goudevenou; David O'Connor; Stella T Chou; Mitchell J Weiss; Anastasios Karadimitris; Sten Eirik Jacobsen; Paresh Vyas; Irene Roberts
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-08       Impact factor: 11.205

7.  Myeloid Proliferations Associated with Down Syndrome.

Authors:  Alan B Cantor
Journal:  J Hematop       Date:  2014-12-14       Impact factor: 0.196

8.  Developmental Stage-Specific Manifestations of Absent TPO/c-MPL Signalling in Newborn Mice.

Authors:  Viola Lorenz; Haley Ramsey; Zhi-Jian Liu; Joseph Italiano; Karin Hoffmeister; Sihem Bihorel; Donald Mager; Zhongbo Hu; William B Slayton; Benjamin T Kile; Martha Sola-Visner; Francisca Ferrer-Marin
Journal:  Thromb Haemost       Date:  2017-12-06       Impact factor: 5.249

9.  Reduced Erg Dosage Impairs Survival of Hematopoietic Stem and Progenitor Cells.

Authors:  Ying Xie; Mia Lee Koch; Xin Zhang; Melanie J Hamblen; Frank J Godinho; Yuko Fujiwara; Huafeng Xie; Jan-Henning Klusmann; Stuart H Orkin; Zhe Li
Journal:  Stem Cells       Date:  2017-04-24       Impact factor: 6.277

10.  Perturbation of fetal hematopoiesis in a mouse model of Down syndrome's transient myeloproliferative disorder.

Authors:  Yehudit Birger; Liat Goldberg; Timothy M Chlon; Benjamin Goldenson; Inna Muler; Ginette Schiby; Jasmin Jacob-Hirsch; Gideon Rechavi; John D Crispino; Shai Izraeli
Journal:  Blood       Date:  2013-05-29       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.